WO1999032152A3 - Methods for delivering pharmaceutical agents to mucosal surfaces - Google Patents

Methods for delivering pharmaceutical agents to mucosal surfaces Download PDF

Info

Publication number
WO1999032152A3
WO1999032152A3 PCT/US1998/027410 US9827410W WO9932152A3 WO 1999032152 A3 WO1999032152 A3 WO 1999032152A3 US 9827410 W US9827410 W US 9827410W WO 9932152 A3 WO9932152 A3 WO 9932152A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical agents
methods
incorporated
delivery system
mucosal surfaces
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/027410
Other languages
French (fr)
Other versions
WO1999032152A2 (en
Inventor
Vladimir Kharitonov
Helen M Ranney
Leo Trevino
Stephen G Flore
Luis A Dellamary
Lorraine E Reeve
Jeffry G Weers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MDV Technologies Inc
Original Assignee
MDV Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MDV Technologies Inc filed Critical MDV Technologies Inc
Priority to AU19438/99A priority Critical patent/AU1943899A/en
Publication of WO1999032152A2 publication Critical patent/WO1999032152A2/en
Publication of WO1999032152A3 publication Critical patent/WO1999032152A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Delivery systems and methods of delivering pharmaceutical agents to a hydrophobic region of an animal, particularly a mucosal surface, such as the mucosal lining of the gastrointestinal (GI) tract, are disclosed. In one embodiment, one or more pharmaceutical agents are incorporated into a delivery system comprising a constitutive polymer, such as a poloxamer, and, optionally, one or more modifier polymers (e.g., carboxymethylcellulose) and/or one or more hydrophilic co-surfactants (e.g., a fatty acid soap). In another embodiment, one or more pharmaceutical agents are incorporated into a delivery system comprising a reverse emulsion, which comprises a disperse polar phase, a continuous lipophilic phase, and one or more emulsifying agents (e.g., a surfactant). The disclosed compositions and methods are useful in the treatment of, for example, gastric H. pylori infection, where the incorporated pharmaceutical agent is an antibiotic.
PCT/US1998/027410 1997-12-23 1998-12-23 Methods for delivering pharmaceutical agents to mucosal surfaces Ceased WO1999032152A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU19438/99A AU1943899A (en) 1997-12-23 1998-12-23 Methods for delivering pharmaceutical agents to mucosal surfaces

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
USPCT/US97/23865 1997-12-23
PCT/US1997/023865 WO1999032151A1 (en) 1997-12-23 1997-12-23 Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions

Publications (2)

Publication Number Publication Date
WO1999032152A2 WO1999032152A2 (en) 1999-07-01
WO1999032152A3 true WO1999032152A3 (en) 1999-12-09

Family

ID=22262364

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1997/023865 Ceased WO1999032151A1 (en) 1997-12-23 1997-12-23 Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions
PCT/US1998/027410 Ceased WO1999032152A2 (en) 1997-12-23 1998-12-23 Methods for delivering pharmaceutical agents to mucosal surfaces

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US1997/023865 Ceased WO1999032151A1 (en) 1997-12-23 1997-12-23 Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions

Country Status (5)

Country Link
EP (1) EP1039932A1 (en)
JP (1) JP2001526246A (en)
AU (2) AU753206B2 (en)
CA (1) CA2316248A1 (en)
WO (2) WO1999032151A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223826B2 (en) 2003-01-30 2007-05-29 3M Innovative Properties Company Amide-functional polymers, compositions, and methods
US9486405B2 (en) 2013-08-27 2016-11-08 Otonomy, Inc. Methods for the treatment of pediatric otic disorders

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0887076A3 (en) * 1997-05-07 1999-03-31 Saturnus A.G. Adhesion prevention and an endoscopic insufflation system therefor
US6881420B2 (en) 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
DK1392254T3 (en) 2001-04-20 2007-07-02 Univ British Columbia Micelle drug delivery system for hydrophobic drugs
EP1414497A4 (en) * 2001-08-08 2007-11-21 Univ Florida Novel microemulsion and micelle systems for solubilizing drugs
US7138133B2 (en) 2001-10-10 2006-11-21 The Procter & Gamble Company Orally administered liquid compositions
WO2004012791A2 (en) * 2002-08-06 2004-02-12 Genvec, Inc. Improved injection system
US20040151691A1 (en) 2003-01-30 2004-08-05 Oxman Joel D. Hardenable thermally responsive compositions
US8802116B2 (en) 2003-02-27 2014-08-12 Novasel Australia Pty. Ltd. Poloxamer emulsion preparations
JP4473539B2 (en) * 2003-08-12 2010-06-02 エスエス製薬株式会社 Pharmaceutical composition
WO2005079856A1 (en) * 2004-02-23 2005-09-01 The University Of British Columbia Drug delivery compositions comprising hydrophobic polymers and amphipathic molecules
WO2007089103A1 (en) 2006-02-01 2007-08-09 Samyang Corporation Composition for inhibiting adhesion
US8062282B2 (en) 2006-02-13 2011-11-22 Fossa Medical, Inc. Methods and apparatus for temporarily occluding body openings
WO2009139924A2 (en) 2008-05-14 2009-11-19 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of otic disorders
WO2010011466A2 (en) 2008-06-27 2010-01-28 Otonomy, Inc. Controlled-release cns modulating compositions and methods for the treatment of otic disorders
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
MX2011000862A (en) * 2008-07-21 2011-03-15 Otonomy Inc Controlled release antimicrobial compositions and methods for the treatment of otic disorders.
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
JP2013508381A (en) * 2009-10-21 2013-03-07 オトノミ―，インク． Control of the gelation temperature of formulations containing poloxamers
EP3508197A1 (en) * 2009-10-21 2019-07-10 Otonomy, Inc. Modulation of gel temperature of poloxamer-containing formulations
JP6143286B2 (en) * 2013-05-13 2017-06-07 学校法人 関西大学 Anti-adhesion material and method for producing the same
SG11201609593RA (en) * 2014-05-16 2016-12-29 Ultrast Inc Phase-shifting formulations
CN106659823B (en) * 2014-07-24 2019-11-12 玫帝托克斯股份有限公司 Thermally responsive anti-blocking composition and use thereof
WO2018053173A1 (en) 2016-09-16 2018-03-22 Otonomy, Inc. Otic gel formulations for treating otitis externa
JP6403297B2 (en) * 2017-05-02 2018-10-10 川澄化学工業株式会社 Method for producing anti-adhesion material

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0274431A2 (en) * 1987-01-08 1988-07-13 Quixote Corporation Drug delivery compositions and methods
WO1990004971A1 (en) * 1988-11-03 1990-05-17 M.D.R. Group, Inc. Improved viscoelastic fluid for use in surgery and other therapies and method of using same
EP0455396A1 (en) * 1990-05-01 1991-11-06 MDV Technologies, Inc. Aqueous gel compositions and their use
US5126141A (en) * 1988-11-16 1992-06-30 Mediventures Incorporated Composition and method for post-surgical adhesion reduction with thermo-irreversible gels of polyoxyalkylene polymers and ionic polysaccharides
EP0551626A1 (en) * 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
WO1994003157A1 (en) * 1992-07-28 1994-02-17 Poli Industria Chimica S.P.A. Pharmaceutical compositions for transmucosal delivery of peptides
EP0598116A1 (en) * 1989-11-27 1994-05-25 Nippon Shinyaku Company, Limited Fat emulsion
WO1994014415A1 (en) * 1992-12-24 1994-07-07 Hemagen/Pfc Fluorocarbon emulsions
US5369131A (en) * 1991-04-24 1994-11-29 Poli Industria Chimica S.P.A. Oral, cutaneous and intravaginal pharmaceutical compositions in the form of foam
WO1995009626A1 (en) * 1993-10-01 1995-04-13 Syntex (U.S.A.) Inc. Mycophenolate mofetil high dose oral suspensions
WO1995024430A2 (en) * 1994-03-04 1995-09-14 University Of Washington Block and graft copolymers and methods relating thereto
US5484610A (en) * 1991-01-02 1996-01-16 Macromed, Inc. pH and temperature sensitive terpolymers for oral drug delivery
EP0694310A1 (en) * 1993-04-16 1996-01-31 Wakamoto Pharmaceutical Co., Ltd. Reversible, thermally gelling water-base medicinal composition
WO1996020696A1 (en) * 1994-12-30 1996-07-11 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810503A (en) * 1987-03-31 1989-03-07 Basf Corporation Polymers which form gels at low concentrations in water
US4911926A (en) * 1988-11-16 1990-03-27 Mediventures Inc. Method and composition for reducing postsurgical adhesions
JP2926749B2 (en) * 1989-04-25 1999-07-28 吉富製薬株式会社 Prostaglandin-containing liquid composition
US5252318A (en) * 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
US5264047A (en) * 1991-07-17 1993-11-23 Church & Dwight Co., Inc. Low foaming effective hydrotrope

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0274431A2 (en) * 1987-01-08 1988-07-13 Quixote Corporation Drug delivery compositions and methods
WO1990004971A1 (en) * 1988-11-03 1990-05-17 M.D.R. Group, Inc. Improved viscoelastic fluid for use in surgery and other therapies and method of using same
US5126141A (en) * 1988-11-16 1992-06-30 Mediventures Incorporated Composition and method for post-surgical adhesion reduction with thermo-irreversible gels of polyoxyalkylene polymers and ionic polysaccharides
EP0598116A1 (en) * 1989-11-27 1994-05-25 Nippon Shinyaku Company, Limited Fat emulsion
EP0455396A1 (en) * 1990-05-01 1991-11-06 MDV Technologies, Inc. Aqueous gel compositions and their use
US5484610A (en) * 1991-01-02 1996-01-16 Macromed, Inc. pH and temperature sensitive terpolymers for oral drug delivery
US5369131A (en) * 1991-04-24 1994-11-29 Poli Industria Chimica S.P.A. Oral, cutaneous and intravaginal pharmaceutical compositions in the form of foam
EP0551626A1 (en) * 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
WO1994003157A1 (en) * 1992-07-28 1994-02-17 Poli Industria Chimica S.P.A. Pharmaceutical compositions for transmucosal delivery of peptides
WO1994014415A1 (en) * 1992-12-24 1994-07-07 Hemagen/Pfc Fluorocarbon emulsions
EP0694310A1 (en) * 1993-04-16 1996-01-31 Wakamoto Pharmaceutical Co., Ltd. Reversible, thermally gelling water-base medicinal composition
WO1995009626A1 (en) * 1993-10-01 1995-04-13 Syntex (U.S.A.) Inc. Mycophenolate mofetil high dose oral suspensions
WO1995024430A2 (en) * 1994-03-04 1995-09-14 University Of Washington Block and graft copolymers and methods relating thereto
WO1996020696A1 (en) * 1994-12-30 1996-07-11 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223826B2 (en) 2003-01-30 2007-05-29 3M Innovative Properties Company Amide-functional polymers, compositions, and methods
US9486405B2 (en) 2013-08-27 2016-11-08 Otonomy, Inc. Methods for the treatment of pediatric otic disorders

Also Published As

Publication number Publication date
WO1999032151A1 (en) 1999-07-01
JP2001526246A (en) 2001-12-18
AU753206B2 (en) 2002-10-10
WO1999032152A2 (en) 1999-07-01
AU1943899A (en) 1999-07-12
EP1039932A1 (en) 2000-10-04
AU5533598A (en) 1999-07-12
CA2316248A1 (en) 1999-07-01

Similar Documents

Publication Publication Date Title
WO1999032152A3 (en) Methods for delivering pharmaceutical agents to mucosal surfaces
RU2227018C2 (en) Polymethylidenemalonate-base new microspheres, methods for their preparing and pharmaceutical compositions containing thereof
JP4157969B2 (en) Emulsified drug delivery system
EP1071457B1 (en) Polymer particle vaccine delivery system
ES2279537T3 (en) METHODS AND COMPOSITIONS TO INCREASE THE BIOADHESIVE PROPERTIES OF THE POLYMERS.
WO2003017940A3 (en) Pulsatile release compositions and methods for enhanced gastrointestinal drug absorption
JP5600233B2 (en) Compositions of lipids and cationic peptides
NZ506415A (en) Liquid polymeric compositions for controlled release of bioactive substances using a polymer to active agent ratio of less than 1:1
BR0210505A (en) Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
CA2313024A1 (en) Pharmaceutical compositions containing an omega-3 fatty acid oil
TW223022B (en)
AU2005227090A1 (en) Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
CA2181502A1 (en) Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
JP2003503440A (en) Pharmaceutical composition containing clear oil
IL133196A0 (en) Gastroretentive controlled release pharmaceutical dosage forms
WO1998047491A3 (en) Controlled release formulations using intelligent polymers
EP2298283A3 (en) Pharmaceutical formulations comprising cannabinoids
CA2340056A1 (en) Pharmaceutical compositions containing lipase inhibitors
CA2387361A1 (en) Crystal form 0 and form ii of clarithromycin and uses thereof
SE0202619D0 (en) New Polymers and Applications
MY120798A (en) Medicinal compositions adhering to stomach/duodenum
WO2002067852A3 (en) A controlled release pharmaceutical composition
CN1255052A (en) Emulsifier composition for skin care formulations
CN1514725B (en) Pharmaceutical composition comprising lipase inhibitor and sucrose fatty acid ester
CA2358448A1 (en) Dispersible concentrate for the delivery of cyclosporin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase